Global report - September 1, 2017
Historic approval for Novartis
Novartis has received a FDA approval for its CAR-T treatment tisagenlecleucel, a first-ever cell therapy for a rare form of acute lymphoblastic leukemia. The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up […]
Clinical Trials - June 2, 2016
Genmab anounce Phase III studies
Genmab A/S announces that its collaboration partner Novartis will start Phase III studies of the subcutaneous formulation of ofatumumab in relapsing multiple sclerosis (MS) with enrolment of patients expected to start in September 2016. The studies will compare the efficacy and safety of subcutaneous ofatumumab versus teriflunomide in patients with relapsing MS. Details of the […]
Acquisition - April 22, 2014
Novartis buys GSK oncology unit
GlaxoSmithKline has announced a 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses. The two companies will create a new consumer healthcare business with 2013 pro forma revenues of £6.5 billion. GSK will have majority control with an equity interest of 63.5%. GSK will also acquire Novartis’ global Vaccines business (excluding […]
Agreement - January 10, 2014
Nuevolution Announces Technology Licensing Agreement
Nuevolution has announced that it has entered into a non-exclusive technology licensing agreement with Novartis for use of Nuevolution’s Chemetics technology. The Chemetics platform uses proprietary innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming drug-like small molecules for lead discovery. The technology allows efficient screening of billions of molecules against […]
Collaboration - September 17, 2013
Camurus receives option-exercise milestone for CAM2029
Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal Injection depot technology. The option exercise triggers an undisclosed milestone payment to Camurus from […]
Drug Development Pharma - September 10, 2013
Novartis acquires drug candidate from Camurus
Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus’ FluidCrystal Injection depot technology. The option exercise is the next stage in the collaboration, option […]
